Recent developments in d-α-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy

Cancer remains an obstacle to be surmounted by humans. As an FDA-approved biocompatible drug excipient, d-α-tocopheryl polyethylene glycol succinate (TPGS) has been widely applied in drug delivery system (DDS). Along with in-depth analyses of TPGS-based DDS, increasingly attractive results have reve...

Full description

Saved in:
Bibliographic Details
Published in:Drug delivery 2017-11, Vol.24 (1), p.1831-1842
Main Authors: Tan, Songwei, Zou, Chenming, Zhang, Wei, Yin, Mingxing, Gao, Xueqin, Tang, Qing
Format: Article
Language:English
Subjects:
Animals
Apoptosis
Biomedical materials
Breast cancer
cancer
Cancer therapies
d-α-tocopheryl polyethylene glycol succinate (TPGS)
Drug Carriers - administration & dosage
drug delivery system
Drug delivery systems
Drug Delivery Systems - methods
Humans
Metastasis
Multidrug resistant organisms
multidrug-resistant
nanomedicine
Nanomedicine - methods
Nanoparticles
Neoplasms - drug therapy
Pharmaceutical sciences
Pharmacy
Polyethylene glycol
Review
Tumors
Vitamin E - pharmacology
Vitamin E - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer remains an obstacle to be surmounted by humans. As an FDA-approved biocompatible drug excipient, d-α-tocopheryl polyethylene glycol succinate (TPGS) has been widely applied in drug delivery system (DDS). Along with in-depth analyses of TPGS-based DDS, increasingly attractive results have revealed that TPGS is able to act not only as a simple drug carrier but also as an assistant molecule with various bio-functions to improve anticancer efficacy. In this review, recent advances in TPGS-based DDS are summarized. TPGS can inhibit P-glycoprotein, enhance drug absorption, induce mitochondrial-associated apoptosis or other apoptotic pathways, promote drug penetration and tumor accumulation, and even inhibit tumor metastasis. As a result, many formulations, by using original TPGS, TPGS-drug conjugates or TPGS copolymers, were prepared, and as expected, an enhanced therapeutic effect was achieved in different tumor models, especially in multidrug resistant and metastatic tumors. Although the mechanisms by which TPGS participates in such functions are not yet very clear, considering its effectiveness in tumor treatment, TPGS-based DDS appears to be one of the best candidates for future clinical applications.
ISSN:1071-7544
1521-0464
DOI:10.1080/10717544.2017.1406561